This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.

Inclusion Criteria:

• Ambulatory women
• Diagnosis of post-menopausal osteoporosis
• Women who have never received bisphosphonate therapy, or who have discontinued daily bisphosphonates at least 3 months prior to study entry

Exclusion Criteria:

• Inability to stand or sit in the upright position for greater than or equal to 60 minutes
• Allergy to bisphosphonates;
• Previous or current treatment with weekly or monthly bisphosphonates, or daily bisphosphonates for the last 3 months prior to study entry